Sir, can you highlight in terms of which...
Is this better?
Questions across 2 calls
Naman Bagrecha
IIFL Capital Services Limited
Concord Biotech Limited
Sir, just wanted to understand that on Teriflunomide, at my understanding is that you're targeting both markets seriously, I mean, both in the sense, U.S. and ex -U.S. market as well. While you highlighted that ex U.S. market size would be closer to, let's say, $500 million. Just wanted to understand what is the competitive landscape over there? I mean, what kind of, let's say, market share targets are we keeping in mind?
Okay. And what kind of margins would be there for this product in the U.S. I mean you can probably just say that it is above corporate EBITDA margins or low corporate EBITDA margin that's...